DADina M. Aresvik

Dina M. Aresvik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dina M. Aresvik has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Kari Lima

    Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Tore G. Abrahamsen

    Center for Rare Diseases, Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Torstein Øverland

    Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Camilla Schjalm

    Department of Immunology, Oslo University Hospital and University of Oslo, Oslo, Norway

    1 shared publication
  • K. Lima

    Division of Medicine, Akershus University Hospital, Lørenskog, Norway

    1 shared publication
  • Marianne S Wright

    1 shared publication

Latest Publications

  • Open Access

    Complement Activation in 22q11.2 Deletion Syndrome

    by Dina Grinde, Torstein Øverland, Kari Lima, Camilla Schjalm, Tom Eirik Mollnes, Tore G. Abrahamsen

    The 22q11.2 deletion syndrome (22q11.2 del), also known as DiGeorge syndrome, is a genetic disorder with an estimated incidence of 1:3000 to 1:6000 births. These patients may suffer from affection of many organ systems with cardiac malformations, immunodeficiency, hypoparathyroidism, autoimmunity, palate anomalies, and psychiatric disorders being the most frequent. The importance of the complement system in 22q11.2 del has not been investigated. The objective of this study was to evaluate the complement system in relation to clinical and immunological parameters in patients. A national cohort of patients (n = 69) with a proven heterozygous deletion of chromosome 22q11.2 and a group of age and sex matched controls (n = 56) were studied. Functional capacity of the classical, lectin, and alternative pathways of the complement system as well as complement activation products C3bc and terminal complement complex (TCC) were accessed and correlated to clinical features. All patients in our study had normal complement activation in both classical and alternative pathways. The frequency of mannose-binding lectin deficiency was comparable to the normal population. The patients had significantly raised plasma levels of C3bc and a slight, but not significant, increase in TCC compared with controls. This increase was associated with the presence of psychiatric disorders in patients. The present study shows no complement deficiencies in 22q11.2 deletion syndrome. On the contrary, there are signs of increased complement activation in these patients. Complement activation is particularly associated with the presence of psychiatric disorders.


  • Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome

    by Dina M. Aresvik, Torstein Øverland, Kari Lima, Rolf D. Pettersen, Tore G. Abrahamsen

    Immunodeficiency is one of the key features of 22q11.2 deletion syndrome (del), and it is seen in approximately 75% of the patients. The degree of immunodeficiency varies widely, from no circulating T cells to normal T cell counts. It has been hypothesized that the low number of T cells may at least in part be due to increased apoptosis of T cells. Increased spontaneous T cell apoptosis has been reported in one patient with 22q11.2del, but this has not been further investigated.


  • Open Access

    Increased Levels of Interferon‐Inducible Protein 10 (IP‐10) in 22q11.2 Deletion Syndrome

    by D. M. Aresvik, K. Lima, T. Øverland, T. E. Mollnes, T. G. Abrahamsen

    The 22q11.2 deletion syndrome (22q11.2 DS), also known as DiGeorge syndrome, is a genetic disorder with an estimated incidence of 1:4000 births. These patients may suffer from affection of many organ systems with cardiac malformations, thymic hypoplasia or aplasia, hypoparathyroidism, palate anomalies and psychiatric disorders being the most frequent. The incidence of autoimmune diseases is increased in older patients. The aim of the present study was to examine a cytokine profile in patients with 22q11.2 DS by measuring a broad spectrum of serum cytokines. Patients with a proven deletion of chromosome 22q11.2 (n = 55) and healthy individuals (n = 54) recruited from an age‐ and sex‐comparable group were included in the study. Serum levels of 27 cytokines, including chemokines and growth factors, were analysed using multiplex technology. Interferon‐inducible protein 10 (IP‐10) was also measured by ELISA to confirm the multiplex results. The 22q11.2 DS patients had distinctly and significantly raised levels of pro‐inflammatory and angiostatic chemokine IP‐10 (P < 0.001) compared to controls. The patients with congenital heart defects (n = 31) had significantly (P = 0.018) raised serum levels of IP‐10 compared to patients born without heart defects (n = 24). The other cytokines investigated were either not detectable or did not differ between patients and controls.


    • 1 October 2010
      • Vol. 30  (10) , 3879-87

    5-fluorouracil-induced death of Jurkat T-cells--a role for caspases and MCL-1.

    by Dina M Aresvik, Rolf D Pettersen, Tore G Abrahamsen, Marianne S Wright

    5-Fluorouracil (5-FU) is frequently used in cancer treatment. Previous studies with 5-FU suggest that proapoptotic protein BAX and tumor suppressor protein TP53 are central factors in this process. As the leukemic T cell line Jurkat E6 has mutations in both these genes, we investigated a possible activation of alternative death pathways following 5-FU treatment. Here we show that 5-FU triggers apoptosis in Jurkat cells in a dose-dependent manner. Death responses were only moderately attenuated in the presence of a general caspase inhibitor. However, flow cytometric analysis showed activation of caspase 3 and a slight increase in ROS generation in a time- and dose-dependent manner. Furthermore, we observed 5-FU induced PARP cleavage and notably, reduced expression of antiapoptotic MCL-1L associated with the appearance of proapoptotic MCL-1S. Our results demonstrate the activation of alternative death pathways following treatment with 5-FU, despite mutations in the TP53 and BAX genes.